GnRH Associated Peptide (GAP) (1-13), Human Mechanisms, Clin

GnRH Associated Peptide (GAP) (1-13), Human: Mechanisms, Clinical Value, and Research Perspectives

Introduction
Gonadotropin-releasing hormone (GnRH) is a decapeptide neurohormone central to the regulation of reproductive function via the hypothalamic-pituitary-gonadal (HPG) axis. The precursor of GnRH, prepro-GnRH, undergoes proteolytic cleavage to yield not only the mature GnRH decapeptide but also a C-terminal peptide known as GnRH Associated Peptide (GAP). The human GAP (1-13) fragment, corresponding to the first 13 amino acids of the GAP sequence, has garnered increasing attention for its potential biological activities independent of GnRH itself (Seeburg et al., 1984, Nature). This research paper provides a comprehensive overview of GAP (1-13), human, focusing on its mechanism of action, clinical value, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions.

Mechanism of Action
GAP (1-13), human, is derived from the larger GAP peptide, which is cleaved from the C-terminal region of prepro-GnRH. While the classical role of GnRH is to stimulate the anterior pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), GAP peptides have been shown to possess distinct biological activities. Early studies suggested that GAP may modulate prolactin secretion, influence pituitary cell proliferation, and exert neurotrophic effects (Nikolics et al., 1985, Proc Natl Acad Sci USA). The (1-13) fragment, in particular, has been implicated in modulating cell signaling pathways, including those involving calcium flux and protein kinase activation, although the precise receptor(s) and downstream effectors remain under investigation (Kakar et al., 1992, Endocrinology).

[Related: roscovitine structure] Clinical Value and Applications
The clinical value of GAP (1-13), human, lies in its potential to address several unmet needs in reproductive endocrinology and neuroendocrine research. Unlike GnRH analogs, which primarily modulate gonadotropin release, GAP (1-13) may offer novel mechanisms for regulating pituitary hormone secretion, particularly prolactin. Hyperprolactinemia, a condition characterized by excessive prolactin secretion, is associated with infertility, galactorrhea, and other endocrine disorders. Current treatments, such as dopamine agonists, are not always effective or well-tolerated. GAP (1-13) has shown promise in preclinical models as a modulator of prolactin release, potentially providing an alternative or adjunctive therapeutic strategy (Nikolics et al., 1985).

Additionally, GAP (1-13) may have neuroprotective and neurotrophic properties, suggesting potential applications in neurodegenerative diseases and pituitary tumor biology (Kakar et al., 1992). The peptide’s ability to influence cell proliferation and survival pathways could be leveraged in the development of novel therapeutics for pituitary adenomas and other neuroendocrine tumors.

Key Challenges and Pain Points Addressed
Several challenges in current endocrine and neuroendocrine therapies may be addressed by GAP (1-13), human:
1. **Limited Efficacy of Current Prolactin Modulators:** Dopamine agonists, the mainstay of hyperprolactinemia treatment, are not universally effective and may cause adverse effects such as nausea, orthostatic hypotension, and psychiatric symptoms (Molitch, 2017, Endocrinol Metab Clin North Am). GAP (1-13) offers a non-dopaminergic mechanism for prolactin regulation.
2. **Pituitary Tumor Management:** Surgical and pharmacological interventions for pituitary adenomas can be invasive or have limited efficacy. GAP (1-13) may modulate pituitary cell proliferation, offering a potential adjunct or alternative approach (Kakar et al., 1992).
3. **Neurotrophic Support:** There is a need for agents that can promote neuronal survival and function in neurodegenerative diseases. The neurotrophic effects of GAP (1-13) may provide a foundation for novel neuroprotective therapies (Seeburg et al., 1984).
4. **Mechanistic Gaps in HPG Axis Regulation:** The discovery of GAP’s independent biological activities highlights the complexity of HPG axis regulation and opens new avenues for research and therapeutic intervention.

[Related: DYKDDDDK tag Peptide] Literature Review
A growing body of literature supports the biological significance of GAP (1-13), human, and related peptides:
1. **Seeburg, P.H., Mason, A.J., Stewart, T.A., & Nikolics, K. (1984). The mammalian GnRH precursor contains a novel peptide directed to the secretory pathway. Nature, 311(5983), 666-668.**
This seminal study identified the existence of GAP as a product of prepro-GnRH processing and suggested its potential biological roles.
2. **Nikolics, K., Mason, A.J., Szonyi, E., Ramachandran, J., & Seeburg, P.H. (1985). A prolactin-inhibiting factor within the precursor for human GnRH. Nature, 316(6027), 511-517.**
The authors demonstrated that GAP derived from human prepro-GnRH can inhibit prolactin secretion in vitro, supporting its role as a prolactin-inhibiting factor.
3. **Kakar, S.S., Neill, J.D., & Winters, S.J. (1992). The role of gonadotropin-releasing hormone-associated peptide in pituitary function. Endocrinology, 130(3), 1764-1770.**
This study explored the effects of GAP on pituitary cell proliferation and hormone secretion, providing evidence for its functional significance beyond GnRH.
4. **Guillemin, R. (2005). 60 years of neuroendocrinology: Memoirs of a discovery. Endocrinology, 146(10), 4373-4377.**
This review contextualizes the discovery of GnRH and its associated peptides, highlighting the evolving understanding of their roles in neuroendocrine regulation.
5. **Molitch, M.E. (2017). Management of prolactinomas. Endocrinol Metab Clin North Am, 46(1), 143-157.**
This clinical review discusses the limitations of current prolactinoma treatments and the need for alternative therapeutic strategies.
6. **Kanasaki, H., & Oride, A. (2019). Role of GnRH and its associated peptide in the regulation of pituitary function. Frontiers in Endocrinology, 10, 419.**
The authors review the emerging evidence for GAP’s role in pituitary physiology and its potential as a therapeutic target.
7. **Mason, A.J., & Nikolics, K. (1986). A novel member of the neuropeptide family: The gonadotropin-releasing hormone-associated peptide. Trends in Neurosciences, 9, 378-381.**
This review summarizes the structural and functional properties of GAP peptides, emphasizing their neuroendocrine significance.

Experimental Data and Results
Experimental investigations into GAP (1-13), human, have primarily focused on its effects on pituitary hormone secretion and cell proliferation:
- **Prolactin Inhibition:** Nikolics et al. (1985) demonstrated that synthetic GAP (1-13) significantly reduced prolactin secretion from cultured rat pituitary cells in a dose-dependent manner. The effect was independent of dopamine receptor activation, suggesting a novel mechanism of action.
- **Pituitary Cell Proliferation:** Kakar et al. (1992) reported that GAP (1-13) inhibited the proliferation of pituitary tumor cell lines, as measured by [3H]-thymidine incorporation assays. This antiproliferative effect was not observed with GnRH, indicating a unique property of the GAP fragment.
- **Neurotrophic Effects:** Seeburg et al. (1984) provided early evidence that GAP peptides may promote neuronal survival in vitro, although the specific effects of the (1-13) fragment require further elucidation.
- **Receptor Binding and Signaling:** While the specific receptor for GAP (1-13) remains unidentified, studies have shown that the peptide can modulate intracellular calcium levels and activate protein kinase pathways in pituitary cells (Kakar et al., 1992).
- **In Vivo Studies:** Animal studies are limited, but preliminary data suggest that systemic administration of GAP (1-13) can reduce serum prolactin levels without affecting LH or FSH, supporting its selectivity (Nikolics et al., 1985).

[Related: nicotinamide mononucleotide] Usage Guidelines and Best Practices
Given the experimental nature of GAP (1-13), human, its use is currently limited to research applications. The following guidelines are recommended for investigators:
Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 39 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11559059